Harvard Pilgrim, Lilly partner on Trulicity outcomes

Under a deal with regional payer Harvard Pilgrim Health Care Inc. (Boston, Mass.), the reimbursement and rebate amount for diabetes drug Trulicity dulaglutide from Eli Lilly and Co. (NYSE:LLY) will hinge on

Read the full 329 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE